Commercialization Agreements, Acquisition Updates, Conference Calls Schedules, Stock Price Updates and Clinical Study Data -

Commercialization Agreements, Acquisition Updates, Conference Calls Schedules,
Stock Price Updates and Clinical Study Data - Research Report on Biogen Idec,
                  Covidien, Vertex, Endo, and Momenta Pharma

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 31, 2013

NEW YORK, December 31, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Biogen
Idec Inc. (NASDAQ: BIIB), Covidien plc (NYSE: COV), Vertex Pharmaceuticals
Incorporated (NASDAQ: VRTX), Endo Health Solutions Inc. (NASDAQ: ENDP), and
Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Biogen Idec Inc. Research Report

On December 17, 2013, Biogen Idec Inc. (Biogen Idec) and Samsung Bioepis
announced that through their joint venture, Biogen Idec has exercised its
right to enter into an agreement to commercialize anti-TNF biosimilar product
candidates in Europe, including biosimilars for widely used therapies to treat
conditions such as rheumatoid arthritis and Crohn's disease. Biogen Idec
informed that under the terms of the agreement, it will be responsible for
commercialization of these product candidates across Europe, where there
already exists a strong market for biosimilars and a defined regulatory
pathway. Tony Kingsley, Executive Vice President of Global Commercial
Operations for Biogen Idec, said, "This is a unique opportunity for us to
leverage our experience in developing and manufacturing high-quality biologics
in therapeutic areas where we are deeply focused, and provide medicines to
patients where there is a significant societal need. As a company that aims to
make a difference in the lives of patients with serious diseases, we are
excited by the potential to offer additional highly effective therapies in
critical areas where there is growing demand." The Full Research Report on
Biogen Idec Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b95b_BIIB

--

Covidien plc Research Report

On December 19, 2013, Covidien plc (Covidien) announced that it will report
its Q1 FY 2014 results on January 24, 2013. The Company said that it will host
a conference call for investors on the same day at 8:30 a.m. ET, and
interested parties may access the same through a webcast at the Company's
website. According to the Company, a replay of the conference call will be
available beginning at 11:30 a.m. ET on January 24, 2014, and ending at 5:00
p.m. on January 31, 2014. The Full Research Report on Covidien plc - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/a14c_COV

--

Vertex Pharmaceuticals Incorporated Research Report

On December 19, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced
data from a Phase 3 study of ivacaftor in 69 people 6 years of age and older
with cystic fibrosis (CF) who have the R117H mutation. Vertex informed that in
the study, the mean absolute treatment difference in the change from baseline
in percent predicted FEV[1] between treatment with ivacaftor and placebo was
2.1% percentage points (p=0.20) and the mean relative treatment difference in
percent predicted FEV[1] was 5.0% (p= 0.06) through the 24-week treatment
period among all patients (intent-to-treat analysis). The Company added that
the study did not meet its primary endpoint of the absolute change from
baseline FEV[1] (percent predicted forced expiratory volume in one second,
FEV[1]) throughout the treatment period for ivacaftor compared to placebo
across all patients. Lastly, Vertex informed that a pre-specified subset
analysis in patients 18 years of age and older (n=50) showed statistically
significant improvements in lung function and other key secondary endpoints.
The Full Research Report on Vertex Pharmaceuticals Incorporated - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/e696_VRTX

--

Endo Health Solutions Inc. Research Report 

On December 19, 2013, Endo Health Solutions Inc. (Endo) announced that the
waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended (HSR Act) regarding Endo's proposed acquisition of Paladin Labs
Inc. (Paladin Labs) was terminated by the U.S. Federal Trade Commission on
December 17, 2013. The Company stated that the Canadian Competition Bureau
issued a no-action letter on December 18, 2013, which constitutes Canadian
Competition Act compliance for Endo's proposed acquisition of Paladin Labs.
Endo stated that the early termination of the HSR waiting period in the United
States and the no-action letter obtained from the Canadian Competition Bureau
in Canada satisfy conditions to the proposed acquisition. According to the
Company, the proposed acquisition remains subject to certain conditions and
approvals, including regulatory approvals, approval by shareholders of Endo
and Paladin Labs, approval of the Superior Court of Quebec, registration and
listing of New Endo shares and customary closing conditions. The Full Research
Report on Endo Health Solutions Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/059c_ENDP

--

Momenta Pharmaceuticals Inc. Research Report

On December 26, 2013, Momenta Pharmaceuticals Inc.'s (Momenta Pharmaceuticals)
stock gained 0.68%, ending the day's trading session at $17.65. Over the
previous three trading sessions, shares of Momenta Pharmaceuticals gained
1.44%, compared to the Nasdaq Composite Index which gained 1.52% during the
same period. The Full Research Report on Momenta Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c334_MNTA

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.  

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)